Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Screensys GmbH currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are divided between 2 distinct examiners, indicating that each pending matter is being handled by a different individual. This setup provides a small degree of examiner diversity for the company's current filings.
The prosecution is active in 2 distinct art units, matching the number of examiners and pending actions. STOCKDALE, JESSICA NICOLE is the busiest examiner for the portfolio, with 1 pending office action currently under review. Since the busiest examiner pending count is 1, the 2 pending office actions are distributed equally between the two examiners involved.
For a practitioner, this means that the 2 pending office actions are being evaluated in two different environments within the patent office. Each of the 2 distinct art units may have its own specific focus or preferred prior art sources. Success in these matters will depend on addressing the unique requirements of each of the 2 distinct examiners, as neither one holds a majority of the pending workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKDALE, JESSICA NICOLE | 1 | 51.4% | +33.3% |
| SCHNASE, PAUL DANIEL | 1 | 67.7% | +7.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555345 | SYSTEMS AND METHODS FOR MICROSCOPIC OBJECT HANDLING | SCHNASE, PAUL DANIEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720938 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | STOCKDALE, JESSICA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| 2800 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720938 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | STOCKDALE, JESSICA NICOLE | 1663 | §103 | Final Rejection | — | Pending | Jun 17, 2024 |
| 18555345 | SYSTEMS AND METHODS FOR MICROSCOPIC OBJECT HANDLING | SCHNASE, PAUL DANIEL | 2800 | §102§103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScreensys GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jessica Nicole Stockdale has the most, with 1 of Screensys GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
